• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

3v.org

Venture Capital Matters

  • Pitch a Startup
    • Make a Contribution
  • Market Reports
  • Technologies
    • Technology Events
  • Domain Names for Startups
  • About
  • Contact

ZielBio Closes $25.1 Million Series A Financing to Enable Development of Monoclonal Antibody ZB131

September 26, 2019 By admin Leave a Comment

ZielBio, Inc., an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes, has closed a $25.1 million Series A financing round. The round is led by Morningside Venture Investments and Partners Innovation Fund (PIF). ZielBio’s lead candidate ZB131 is a proprietary humanized monoclonal antibody against cell surface plectin (CSP), a target that is highly expressed on the plasma membrane of multiple types of cancer cells, including ovarian, pancreatic, lung and colorectal. The funding will enable the company to conduct further research to prioritize potential cancer applications, validate additional targets and initiate a planned phase 1 clinical trial with ZB131. “We are excited to partner with Morningside and PIF whose resources and drug development experience will greatly accelerate ZB131 development,” noted Kimberly Kelly, PhD, President and Chief Science Officer at ZielBio.

“Since its first discovery by ZielBio founder Dr. Kimberly Kelly at Massachusetts General Hospital, we have been encouraged by the unique role that cell surface plectin plays in proliferation, migration and cell survival and its potential as a drug target for a range of difficult to treat cancers,” said PIF Partner Meredith Fisher, PhD. “Extensive pre-clinical laboratory and animal research has demonstrated that ZB131 has a high affinity to bind to CSP, inducing growth arrest and necrosis of targeted tumor cells.”

“Despite the incredible progress being made in immuno-oncology, current therapies have limits and there remains a profound need for new targets and options for many deadly cancers,” said Jason Dinges, JD, PhD, Investment Advisor at Morningside Technology Advisory. “ZB131 has shown potentially superior immune activation to current checkpoint inhibitors and greater direct tumor cell killing than EGFR inhibitors.”

In connection with the financing, Drs. Dinges and Fisher have joined Dr. Kelly on the ZielBio Board of Directors.

About ZielBio
ZielBio is an early-stage biotechnology company that identifies novel disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind™ combines the power of functional, high throughput screening with large content data analytics to identify high value targets. ZielBio has a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP), a cancer target identified through Zielfind™.

Filed Under: PR Tagged With: Monoclonal Antibody

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

Indonesia has the fastest-growing population of smartphone users in the world
DeFiRetailing.com (DeFi Retailing): DeFi will change retail as we know it
VCmatters.com: India overtook the UK to rank third among nations having the most number of unicorns
Australia approves a drought-tolerant genetically modified strain of wheat for use in food
AfricanInvesting.com (African Investing): Rapid acceleration of the African Tech ecosystem
The U.S.’s blood supply had dipped to levels that the Red Cross has not seen in 10 years
China wants to produce its own hard-­tech companies in order to become less reliant on the hostile West

Market Research Media

InfluenceMgmt.com (Influence Management): Formal vs Informal Influence
There will be three to four million product managers globally by 2025
ImpactfulTrends.com (Impactful Trends): Trends to Watch in 2022
PublicDonmain.ai: You can’t copyright AI-created art
Web3.ag: Web3 Crash Course
NFTphotomarketplace.com: NFT Photo Marketplace
White House hosts tech summit to discuss open-source security after Log4j

Secondary Sidebar

Technologies

Organizations are using a wider range of intelligent automation technologies
Fluence and Rich Electric Announce Partnership to Deploy the First 100 MW level Battery-Based Energy Storage System in Taiwan
Quantum-enabled technologies could put the world on track to becoming net-zero
Introducing IonQ Forte, Improving Quantum Performance with a Software-Configurable Dynamic Laser System
Intel Launches Integrated Photonics Research Center

Tech Events

The 58th Design Automation Conference (DAC) will be held at Moscone West Center in San Francisco, CA, from December 5-9, 2021, co-located with SEMICON West 2021, December 7-9 at Moscone North and South halls
NVIDIA GPU Technology Conference, October 5-9, 2020
MATLAB EXPO 2022 Online Conference, May 17–18, 2022
SIGGRAPH 2021, 9-13 August, 2021
Optical Fiber Conference, OFC 2022, taking place at the San Diego Convention Center from March 6-10, 2022

Footer

Recent Posts

  • Plant-based food innovation company, TMRW Foods, raises C$2 million and prepares for North American launch with Sprouts Farmers Market
  • How to achieving gender balance in management teams
  • When you feel like you’re spiraling
  • After Successful Tax Season, Embedded Tax Platform April Raises $30M Series A from Fintech Veterans
  • Vita Mojo Raises US$30 Million to Help Restaurant and Hospitality Chains in Europe Tackle the Digital Future
  • Nautical Commerce Raises $30M to Scale Multi-Vendor Marketplace Technology
  • Token Announces $13 Million Series B Funding Round and Appointment of New CEO to Disrupt the Authentication Market
  • Konnecto Raises $21M to establish a new category in marketing technology
  • Sharebite, the Leading Food Benefits Platform, Announces Closing of $39 Million Series B Round
  • Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health

Dossier

EVgo Added to Russell 3000® and Russell 2000® Indexes
Mobile monetization firm IronSource will go public through SPAC at $11.1 billion valuation | VentureBeat
Miovision acquires Traffop
SK networks CEO & Chairman Shin-Won Choi Resigns
euNetworks Acquires The Loop Manchester

Press Media Release

Governments Spent at Least €93bn on COVID-19 Vaccines and Therapeutics During the Last 11 Months
Saab to Deliver Combat Training Solutions to the Netherlands
Jio Platforms Ltd and SES Announce Joint Venture to Deliver High-Performance Satellite-Based Broadband Services Across India
AT&T and The Texas A&M University System’s RELLIS Campus to Launch 5G Technology to Promote 5G Innovation, Exploration, Education and Training
PUBLIC SERVICES INTERNATIONAL LAUNCHES INTERACTIVE DOCUMENTARY EXPERIENCE ON GLOBAL HEALTH WORKERS

App Coding

Digital twins transform the efficiency of current business processes
Scrub your code in real-time
Code Intelligence raises $12M Series A
Registered yet for Cloudflare Connect London 2022?
Configit Introduces Breakthrough System-Level Configuration Solution

API Coding

Web3 can take power and control from BigTech
Apiip Expand IP To Location API Services to Verify 1 million+ Requests A Month
Five Steps to a Secure Cloud Architecture
WSO2 Completes $93 Million Series E Growth Funding Round with the Investment from Info Edge
DarkOwl Announces Release of Ransomware API

Copyright © 2022 3v.org

Technologies, Market Analysis & Market Research

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT